Elsevier

European Journal of Cancer

Volume 47, Supplement 3, September 2011, Pages S312-S314
European Journal of Cancer

Current standards and new trends in the primary treatment of colorectal cancer

https://doi.org/10.1016/S0959-8049(11)70183-6Get rights and content

First page preview

First page preview
Click to open first page preview

References (10)

  • DJ Sargent et al.

    Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer

    J Clin Oncol

    (2010)
  • G Hutchins et al.

    Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer

    J Clin Oncol

    (2011)
  • R Salazar et al.

    Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer

    J Clin Oncol

    (2011)
  • L Teixeira et al.

    Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors

    J Clin Oncol

    (2010)
  • F Di Nicolantonio et al.

    Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

    J Clin Oncol

    (2008)
There are more references available in the full text version of this article.

Cited by (0)

View full text